Blog
REPROCELL’s Global Biorepository, the solution to your human tissue sample requirements
Our biorepository's carefully governed infrastructure ensures specimens are collected, processed, stored, and distributed under rigorous, standardized conditions.
23 October 2025
.jpg?width=1000&height=562&name=blog%20images%20(1).jpg)
How Human Tissue Testing Adds Commercial Value for Shareholders
Discover how human tissue testing enhances shareholder value, exploring its impact on drug discovery, precision medicine, and regenerative medicine within the life sciences industry.
03 September 2025
Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025
Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.
02 September 2025
NIH Announces End to Exclusive Funding for Animal Model Research
NIH ends exclusive funding for animal model research, promoting New Approach Methodologies like organ-on-a-chip systems and human tissue testing.
18 August 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Find out how our bespoke human tissue equivalents provide new research tools to advance discovery, aid testing in product development, and provide alternatives to the use of animals.
6 November
Meet us at REPROCELL booth and learn about our CLINICAL STEM CELL SERVICES at the ISSCR International Symposium 2025 / 11-12 December / Boston MA, USA
11-12 December
Corporate News
REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
REPROCELL USA receives Maryland Stem Cell Research Fund grant to develop GMP-grade CDMO and iMSC capabilities, enhancing their regenerative medicine and stem cell therapy manufacturing infrastructure.
22 October 2025
REPROCELL Launches Next-Generation System for 3D Bioengineered Tissues
REPROCELL launches Alvetex® Advanced, enhancing 3D cell culture and bioengineered tissue models with improved flexibility and assay compatibility for pharmaceuticals, cosmetics, and medical device testing.
21 October 2025
REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.
20 October 2025